Dec. 15, 2007
Audio Journal of Oncology, December 15th, 2007 Reporting from: San Antonio Breast Cancer Symposium, 13-16 December, 2007 ATAC Trial: Anastrozole Still Superior At Over Eight Years’ Follow Up JACK CUZICK, Wolfson Institute of Preventive Medicine, London REFERENCE: ABSTRACTS 41, 2069, 2071 New data from the ATAC trial, which is testing anastrozole and tamoxifen in early breast cancer, have demonstrated the continued superiority of the aromatase inhibitor. Among other things, the data now show a benefit in the time to distant recurrence. Derek Thorne heard more from Jack Cuzick, of the Wolfson Institute of Preventive Medicine in London.
